Schizophrenia.com
Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort
News
firemonkey
May 21, 2021, 11:11am
1
1 Like
Related topics
Topic
Replies
Views
Activity
All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis
News
1
30
August 22, 2024
Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia
News
0
181
May 11, 2021
Long-Acting Injectables Reduce Disease Relapse in Schizophrenia
News
0
317
August 1, 2022
Oral Versus Long-Acting Injectable Antipsychotic Treatment for People With Severe Schizophrenia: A 5-Year Follow-up of Effectiveness
News
0
218
January 27, 2021
Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia
News
1
310
June 2, 2022